AAN 2018: Novel therapy for ‘difficult-to-treat’ migraines revealed

Written by Sharon Salt, Editor

According to a preliminary Phase IIIB LIBERTY trial presented at the American Academy of Neurology’s 70th Annual Meeting (April 21–27, CA, USA), researchers have disclosed that a monoclonal antibody – termed erenumab – could prevent difficult-to-treat migraines in individuals who have tried unsuccessfully to prevent their migraines with other treatments. Aimovig™ (erenumab) is a monoclonal antibody that blocks pain signals by targeting a receptor for calcitonin gene-related peptide (CGRP), which is known to transmit migraine pain signals. Erenumab occupies the nerves to which CGRP would usually bind. “The people we included in our study were considered more difficult to treat,...

To view this content, please register now for access

It's completely free